PVmed

PVmed was founded by Professor Lu Yao, who serves as President, and Shen Shuo, the CEO. Dr. Lu holds a Ph.D. from the Chinese Academy of Sciences and Syracuse University and was a medical researcher at the University of Michigan Medical School. His background includes serving as the Chief of the Computational Medical Imaging Laboratory at Sun Yat-sen University. Mr. Shen holds a Ph.D. in mathematics from Purdue University and an EMBA from China Europe International Business School, with prior experience as a co-founder of a medical big data service company. Dr. Chenyang Xu, an IEEE Fellow with a Ph.D. from Johns Hopkins University and former CTO of Siemens' North America technology venture arm, is the company's President and Co-Chairman.

The company's product portfolio includes three main solutions: PV-iRT for radiotherapy, PV-iSA for surgical oncology, and PV-iCS for customized software for medical device vendors. A key product, PV-iRT, is an intelligent radiotherapy system that streamlines the entire workflow, from image browsing and target contouring to plan and dose evaluation. Its 'iCurve' feature utilizes AI to automatically contour organs at risk and tumors, significantly reducing the time required for this process from hours to under five minutes. Another offering, PV-iMIP, is an intelligent medical imaging processing system that enhances image quality from various mainstream imaging equipment. These products are designed to process 3D CT and MR data to help doctors plan and treat various cancers, including lung, breast, and nasopharyngeal cancer. The company's solutions have received multiple certifications, including NMPA Class III and FDA 510(k).

Since its inception, PVmed has secured significant funding, including a Seed Round of $1.51 million in October 2017 and a Series A round of $14 million in December 2022 from investors like Philips, Cherami Investment Group, and Strategy Capital. This funding has supported the expansion of its product portfolio and market adoption. The company has established strategic partnerships with major technology companies like Philips and Elekta, and its software is deployed in over 200 hospitals, having been used in the treatment of more than 200,000 cancer patients as of late 2022. Keywords: medical imaging AI, oncology software, radiotherapy planning, surgical oncology, cancer treatment, AI-defined workflow, medical image processing, auto-contouring, auxiliary diagnosis, computed tomography, magnetic resonance imaging, PV-iRT, treatment planning system, clinical decision support, Guangzhou, Chenyang Xu, Lu Yao, Shen Shuo, medical device software, cancer diagnosis